Skip to main content
SpringerLink
Log in

Prognostic Factors of PTLD after SOT

  • Chapter
  • First Online:
Post-Transplant Lymphoproliferative Disorders

  • 353 Accesses

Abstract

Similar to other B-cell malignancies, the prognosis of post-transplant lymphoproliferative disorders (PTLD) subsequent to solid organ transplantation follows comparable principles. Despite remaining one of the most reliable prognostic systems, the International Prognostic Index does not fully hit the mark in regard to the complexity of PTLD and new proposed prognostic factors. Age, performance status, disease stage, and elevated LDH continue to be apropos prognostic factors in PTLD. The heterogeneous nature of PTLD and isolated single-center analyses make validation of updated risk factors difficult to ascertain. Biologic markers will undoubtedly become a backbone of prognostication once validated models become available. While wrought with limitations, when viewed as a conglomerate, certain patterns help provide clinical insight and guidance for practitioners treating PTLD. It is evident additional research in this serious complication of solid organ transplantation will be paramount to identifying future markers to help clinicians better prognosticate PTLD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.

    CAS  PubMed  Google Scholar 

  2. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep. 1977;61:1023–7.

    CAS  PubMed  Google Scholar 

  3. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med. 1993;329(14):987–94.

    Article  Google Scholar 

  4. AJCC: Hodgkin and non-Hodgkin lymphomas. In: Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.p. 607–11.

    Google Scholar 

  5. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    Article  CAS  Google Scholar 

  6. Maniar T, Tsai D. Prognostic Factors for PTLD. Post-Transplant Lymphoproliferative Disorders [Internet]. Springer Berlin Heidelberg; 2010;105–16. Available from: http://dx.doi.org/10.1007/978-3-642-01653-0_8.

  7. Leblond V, Dhedin N, Brunee MF, Choquet S, Hermine O, Porcher R, et al. Identification of prognostic factors in 61 patients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2001;19(3):772–8.

    Article  CAS  Google Scholar 

  8. Tsai DE, Hardy CL, Tomasezewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076–88.

    Article  CAS  Google Scholar 

  9. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinic-pathologically tailored treatment. Haematologica. 2002;87(1):67–77.

    PubMed  Google Scholar 

  10. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005;46:191–6.

    Article  CAS  Google Scholar 

  11. Bakker NA, van Imhoff GW, Verschuuren EAM, van Son WJ, Homan van der Heide JJ, Veeger NJGM, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transpl. 2005;19(3):327–34.

    Article  Google Scholar 

  12. Ghobrial IM, Haberman TM, Macon WR, Ristow KM, Larson TS, Walker RC, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005;79(2):244–7.

    Article  Google Scholar 

  13. Trofe JT, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn international transplant tumor registry experience. Am J Transplant. 2005;5(4):775–80.

    Article  Google Scholar 

  14. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant. 2006;6:2735–42.

    Article  CAS  Google Scholar 

  15. Maecker B, Jack T, Zimmerman M, Abdul-Khalig H, Burdelski M, Fuchs A, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;31:4902–8.

    Article  Google Scholar 

  16. Hourigan MJ, Doecke J, Mollee PN, Gill DS, Norris D, Johnson DW, et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Haematol. 2008;141(6):904–7.

    Article  Google Scholar 

  17. Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008;49:1738–44.

    Article  CAS  Google Scholar 

  18. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354–62.

    Article  Google Scholar 

  19. Evens AM, David KA, Helenaowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–46.

    Article  Google Scholar 

  20. Yoon SO, Cho YE, Suh C, Kim KM, Han DJ, Lee SG, et al. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990–2009. Clin Transpl. 2012;26:67–73.

    Article  Google Scholar 

  21. Trappe RU, Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, et al. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. Am J Transplant. 2015;15:1091–100.

    Article  CAS  Google Scholar 

  22. Bishnoi R, Bajwa R, Franke AJ, Skelton WP, Wang Y, Patel N, et al. Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol. 2017;6:1–14.

    Article  Google Scholar 

  23. Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35:536–43.

    Article  CAS  Google Scholar 

  24. Choquet S, Oertel S, Leblond V, Riess H, Varoqueaux N, Dörken B, et al. Rituximab in the management of post-transplant lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007;86(8):599–607.

    Article  CAS  Google Scholar 

  25. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, et al. Semiquantitative Epstein-Barr virus polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;92(10):3977–8.

    Article  CAS  Google Scholar 

  26. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367:233–9.

    Article  Google Scholar 

  27. Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107:3503–7.

    Article  Google Scholar 

  28. Oertel SH, Vershuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901–6.

    Article  CAS  Google Scholar 

  29. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13:196–206.

    Article  CAS  Google Scholar 

  30. Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37(2):954–5.

    Article  CAS  Google Scholar 

  31. Haldas J, Wang W, Lazarchick J. Post-transplant lymphoproliferative disorders: T-cell lymphoma following cardiac transplant. Leuk Lymphoma. 2002;43(2):447–50.

    Article  Google Scholar 

  32. Lundell R, Elenitoba-Johnson KSJ, Lim MS. T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol. 2004;28(7):967–73.

    Article  Google Scholar 

  33. Benkerrou M, Jais J-P, Leblond V, Durandy A, Sutton L, Bordigoni P, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998;92(9):3137–47.

    Article  CAS  Google Scholar 

  34. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RAF, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006;6:1017–24.

    Article  CAS  Google Scholar 

  35. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23:7574–82.

    Article  Google Scholar 

  36. Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;31:1302–9.

    Article  Google Scholar 

  37. Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant. 2001;20:1054–63.

    Article  CAS  Google Scholar 

  38. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23:6481–8.

    Article  CAS  Google Scholar 

  39. Hayashi RJ, Kraus MD, Patel AL, Canter C, Cohen AH, Hmiel P, et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23:14–8.

    Article  CAS  Google Scholar 

  40. Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé M-L, Meyer C, et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Brit J Haem. 2006;134:602–12.

    Article  CAS  Google Scholar 

  41. Dharnidharka VR, Martz KL, Stablein DM, Benfield MR. Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant. 2011;11:751–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Donald E. Tsai & Mitchell E. Hughes

Authors
  1. Donald E. Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell E. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald E. Tsai .

Editor information

Editors and Affiliations

  1. Washington University School of Medicine and St. Louis Children’s Hospital, Saint Louis, MO, USA

    Vikas R. Dharnidharka

  2. UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Michael Green

  3. Vanderbilt University Medical Center, Nashville, TN, USA

    Steven A. Webber

  4. Ev. Diakonie-Krankenhaus Bremen, German PTLD Study Group, Bremen, Bremen, Germany

    Ralf Ulrich Trappe

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tsai, D.E., Hughes, M.E. (2021). Prognostic Factors of PTLD after SOT. In: Dharnidharka, V.R., Green, M., Webber, S.A., Trappe, R.U. (eds) Post-Transplant Lymphoproliferative Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-65403-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-65403-0_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-65402-3

  • Online ISBN: 978-3-030-65403-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation